LGVN
Longeveron Leaps Ahead: Pivotal Moments in Stem Cell Science
Longeveron, a leading biopharmaceutical company, has made significant strides in its 2025 financial year. In a recent conference call, the company's executives highlighted key developments and future plans that solidify their position as a leader in stem cell research. Stephen Willard, CEO of Longeveron, emphasized the strength of